Max Jan
- Hematology top 1%
- Acute Myeloid Leukemia Research 8
- Multiple Myeloma Research and Treatments 3
- Chronic Myeloid Leukemia Treatments 3
- Immunology top 2%
- Phagocytosis and Immune Regulation 4
- Oncology top 2%
- CAR-T cell therapy research 12
- Aging top 5%
- Genetics top 5%
-
- Protein Degradation and Inhibitors 8
- CRISPR and Genetic Engineering 5
-
- Cancer Genomics and Diagnostics 3
- Co-authors
- Ravindra MajetiIrving L. WeissmanAsh A. AlizadehMark P. ChaoThomas M. SnyderStephen R. QuakeChristopher Y. ParkParesh Vyas
- Cited by
- HematologyImmunologyOncology
- Partner nations
- United StatesSpainUnited Kingdom
In The Last Decade
Max Jan
27 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 86
- Hematology 724
- Immunology 1.4k
- Oncology 1.1k
- Aging 52
- Genetics 252
Countries citing papers authored by Max Jan
This map shows the geographic impact of Max Jan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Jan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Jan more than expected).
Fields of papers citing papers by Max Jan
This network shows the impact of papers produced by Max Jan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Jan. The network helps show where Max Jan may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Max Jan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 3 | |
| 2 | 2024 | 13 | |
| 3 | 2023 | 67 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 0 | |
| 7 | CAR T cell killing requires the IFNγR pathway in solid but not liquid tumoursbreakdown → | 2022 | 225 |
| 8 | 2022 | 88 | |
| 9 | 2022 | 6 | |
| 10 | 2022 | 1 | |
| 11 | 2021 | 180 | |
| 12 | 2021 | 91 | |
| 13 | 2021 | 4 | |
| 14 | 2016 | 74 | |
| 15 | 2015 | 5 | |
| 16 | 2012 | 2 | |
| 17 | 2011 | 87 | |
| 18 | 2011 | 17 | |
| 19 | 2010 | 294 | |
| 20 | Anti-CD47 Antibody Synergizes with Rituximab to Promote Phagocytosis and Eradicate Non-Hodgkin Lymphomabreakdown → | 2010 | 845 |
About Max Jan
Max Jan is a scholar working on Hematology, Aging, Oncology, Molecular Biology and Immunology, having authored 28 papers that have together received 2.9k indexed citations. Recurring topics across this work include CAR-T cell therapy research (12 papers), Acute Myeloid Leukemia Research (8 papers), Protein Degradation and Inhibitors (8 papers), CRISPR and Genetic Engineering (5 papers), Phagocytosis and Immune Regulation (4 papers), Multiple Myeloma Research and Treatments (3 papers), Chronic Myeloid Leukemia Treatments (3 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Hematology (724 citations), Immunology (1.4k citations), Oncology (1.1k citations), Aging (52 citations) and Genetics (252 citations). Max Jan has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Ravindra Majeti, Irving L. Weissman, Ash A. Alizadeh, Mark P. Chao, Thomas M. Snyder, Stephen R. Quake, Christopher Y. Park, Paresh Vyas, M. Ryan Corces and Feifei Zhao. Their work appears in journals such as Blood, Cancer Research, Blood Advances, Science Translational Medicine and Journal of the American Chemical Society.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.